Zelira Therapeutics Limited (ASX:ZLD)
Australia
· Delayed Price · Currency is AUD 0.3500
0.00 (0.00%)
Apr 24, 2025, 3:24 PM AEST
Zelira Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2016 - 2019 |
| Operating Revenue | 0.04 | 0.09 | 0.3 | 1.54 | 0.66 | - | Upgrade
|
| Revenue | 0.04 | 0.09 | 0.3 | 1.54 | 0.66 | - | Upgrade
|
| Revenue Growth (YoY) | -85.34% | -68.47% | -80.45% | 132.26% | - | - | Upgrade
|
| Cost of Revenue | 0.21 | 0.33 | 0.63 | 0.94 | 0.23 | - | Upgrade
|
| Gross Profit | -0.16 | -0.23 | -0.33 | 0.6 | 0.44 | - | Upgrade
|
| Selling, General & Admin | 2 | 2.33 | 5.89 | 7.39 | 5.85 | 3.14 | Upgrade
|
| Research & Development | 2.98 | 2.81 | 1.34 | 1.4 | 2.08 | 3.69 | Upgrade
|
| Other Operating Expenses | 0.07 | 0.01 | 0.12 | 0.23 | 0.11 | 0.1 | Upgrade
|
| Operating Expenses | 3.97 | 5.66 | 6.84 | 13.81 | 9.82 | 7.74 | Upgrade
|
| Operating Income | -4.14 | -5.9 | -7.16 | -13.21 | -9.38 | -7.74 | Upgrade
|
| Interest Expense | -1.38 | -0.74 | -0.08 | -0.05 | -0.04 | -0.01 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | 0.01 | 0 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.61 | 0.64 | 1.03 | 0.9 | 1.05 | 0.84 | Upgrade
|
| EBT Excluding Unusual Items | -4.9 | -5.99 | -6.21 | -12.35 | -8.37 | -6.91 | Upgrade
|
| Impairment of Goodwill | - | -30.75 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.06 | -0.07 | -0.18 | -0.11 | Upgrade
|
| Pretax Income | -4.9 | -36.74 | -6.27 | -12.41 | -8.55 | -7.02 | Upgrade
|
| Earnings From Continuing Operations | -4.9 | -36.74 | -6.27 | -12.41 | -8.55 | -7.02 | Upgrade
|
| Minority Interest in Earnings | 0.06 | 0.17 | 0.7 | 0.47 | - | - | Upgrade
|
| Net Income | -4.84 | -36.57 | -5.57 | -11.95 | -8.55 | -7.02 | Upgrade
|
| Net Income to Common | -4.84 | -36.57 | -5.57 | -11.95 | -8.55 | -7.02 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 10 | 8 | 7 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 10 | 8 | 7 | 5 | Upgrade
|
| Shares Change (YoY) | 3.60% | 12.70% | 25.19% | 21.25% | 36.81% | 12.37% | Upgrade
|
| EPS (Basic) | -0.43 | -3.22 | -0.55 | -1.49 | -1.29 | -1.45 | Upgrade
|
| EPS (Diluted) | -0.43 | -3.22 | -0.55 | -1.49 | -1.29 | -1.45 | Upgrade
|
| Free Cash Flow | -5.29 | -4.39 | -7.25 | -9.43 | -8.62 | -6.95 | Upgrade
|
| Free Cash Flow Per Share | -0.47 | -0.39 | -0.72 | -1.17 | -1.30 | -1.43 | Upgrade
|
| Gross Margin | - | -246.37% | -108.91% | 39.05% | 65.59% | - | Upgrade
|
| Operating Margin | -10120.37% | -6211.63% | -2379.17% | -857.21% | -1414.10% | - | Upgrade
|
| Profit Margin | -11849.86% | -38513.04% | -1850.75% | -775.36% | -1288.84% | - | Upgrade
|
| Free Cash Flow Margin | -12934.93% | -4621.90% | -2407.36% | -611.91% | -1299.02% | - | Upgrade
|
| EBITDA | -3.97 | -5.54 | -6.74 | -12.73 | -9.02 | -7.51 | Upgrade
|
| D&A For EBITDA | 0.17 | 0.35 | 0.42 | 0.47 | 0.36 | 0.23 | Upgrade
|
| EBIT | -4.14 | -5.9 | -7.16 | -13.21 | -9.38 | -7.74 | Upgrade
|
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.